Pediatrix Medical reports Q2 revenue +4.0% to $487.8M, net income $39.8M; buyback program active

Filed August 4, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~1 min read

Key Changes

• high

  Revenue rose 4.0% to $487.8M; net income was $39.8M, up 1.5%, with diluted EPS of $0.49, up 6.5%.

  Key Financials view on EDGAR →
• high

  New up to $250M share repurchase program authorized in August 2025; $145.5M repurchased as of June 30, 2026.

  MD&A: Buyback verify on EDGAR →
• medium

  Repurchased 1,875,462 shares at average $22.77 in Q2 2026, including 1,832,695 under public plans.

  MD&A: Buyback verify on EDGAR →